Natalya Maksimenko

Natalya Maksimenko


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2024 in Kazan Journal of Historical, Linguistic, and Legal Research
Verified
Journal Article
Open access
PDF file
LVLarisa Volova
Larisa Volova
NMNatalya Maksimenko
Natalya Maksimenko
MLM. V. Levina
M. V. Levina
This article substantiates the need for shaping a separate legal system to regulate the relations in tissue banking, as well as biomedical tissue and hybrid technologies. The key problems that have been faced by biomedical and cellular tissue technologies in Russia were analyzed. The major deficiencies and contradictions regarding organ and tissue transplantation in the current Russian legal system were pointed out. First, there have been no federal laws governing the activities of tissue banks. Second, the procedures of human biomaterial donation for medical use remain uncontrolled. Third, there has been no consistency in the retrieval, storage, and transportation of human biomaterials. Finally, the list and legal status of organizations engaged in relevant activities and the legal regime of biological material used for these purposes have not been defined. The study focuses on the practical problems of tissue banks and innovative biomedical technologies that require a legislative initiative. Possible ways to overcome the identified contradictions and problems were discussed.

1 January 2025 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
Denis G. AlekseevDenis G. Alekseev
Denis G. Alekseev
OSOleg Valentinovich Slesarev
Oleg Valentinovich Slesarev
DMDarya Malchikova
Darya Malchikova
VBVyacheslav G. Belanov
Vyacheslav G. Belanov
NMNatalya Maksimenko
Natalya Maksimenko
RARavshanbek B. Abdullaev
Ravshanbek B. Abdullaev
Dry bulk fractions of osteoconductive granular biopolymers (OGB) are a common choice for addressing jawbone defects. These, in conjunction with an insulating biological membrane, form bioengineered scaffold structures. In the recipient site, the OGB fraction undergoes biotransformation, morphing from a bulk granular fraction into a stable conglomerate. The biotransformation of the OGB fraction is a physical process initiated by the biological environment of the recipient site. This process is characterized by granule compaction due to reduced intergranular space volume, leading to an uncontrolled decrease in the planned volume of the OGB. This is one of the causes of postoperative complications.

22 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
OSOleg Valentinovich Slesarev
Oleg Valentinovich Slesarev
DMDarya Malchikova
Darya Malchikova
VPVladimir I. Platonov
Vladimir I. Platonov
NMNatalya Maksimenko
Natalya Maksimenko
AMAlexey A. Melnikov
Alexey A. Melnikov
RARavshanbek Babajonovich Abdullayev
Ravshanbek Babajonovich Abdullayev
Osteoconductive granulated biopolymers (OGB) are used to restore the lost volume of the jaw bone. OGB is employed as a loose fraction and exhibits physical traits common to bulk mixtures. By removing air bubbles and industrial dust from the OGB fraction through special processing, more accessible spaces are left over for the adsorption of bone growth factors. The recipient site's biological environment alters the OGB fraction's physical characteristics. This is the cause of the OGB fraction's volume changing uncontrollably during the first three weeks following surgery. Predictive indicators for describing the physical processes of osteoconduction include the compaction coefficient and adsorption capacity. Taking into account the prognostic indicators of the dynamics of changes in the physical properties of the OGB fraction in the postoperative period, 3D planning of the bioengineered structure should be done. The OGB fraction's adsorption and drainage properties are optimized by raising the purity of OGB production and preparing the biopolymer for clinical studies.